Skip to content
Screener

Travere Therapeutics, Inc. TVTX Q3 2025 earnings

Reported October 30, 2025 · After market close

Revenue$164.9MBeat by $17.9M
EPS$0.28Beat by $0.59
Revenue estimate$147.0M
EPS estimate-$0.31

Next report

Oct 29, 2026 (in a month)
Revenue estimate$195.7M
EPS estimate$0.05

Financials

Q3 2025

Income statement

See full
Revenue$164.9M+162%
Gross profit$163.3M+166%
Operating income$24.9M+144%
Net income$25.7M+147%
EPS (diluted)$0.28+140%

Balance sheet

See full
Cash & equivalents$110.9M+205%
Total debt$18.4M-80.1%
Total equity$73.6M+342%
Total assets$538.6M+6.8%

Cash flow

See full
CapEx$140.0K—

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.13B+96.5%
Enterprise value$2.04B+78.7%
P/S4.9×-0.4×

Profitability

See full
Gross margin97.6%+2.4pp
Operating margin-20.9%-9.8pp
Net margin-20.3%-9.5pp

Returns & leverage

See full
Debt / equity0.2×—
Current ratio2.7×+1.0×

Segments

By segment

See full
Reportable Segment$164.9M+162%

By product

See full
License and collaboration revenue$51.7M+2,626%

FAQ

When did Travere Therapeutics, Inc. report Q3 2025 earnings?
Travere Therapeutics, Inc. (TVTX) reported Q3 2025 earnings on October 30, 2025 after market close.
What were Travere Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Travere Therapeutics, Inc. reported revenue of $164.9M and eps of $0.28 for Q3 2025.
Did Travere Therapeutics, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $147.0M by $17.9M. EPS beat the consensus estimate of $-0.31 by $0.59.
How did Travere Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 162.1% from $62.9M a year earlier.
Where can I find Travere Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001438533-25-000055) and the 10-Q periodic report (0001438533-25-000056) directly on SEC EDGAR. The filing index links above go to sec.gov.